Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Maintenance Dose

<< Previous

Bullboard Posts

Next >>

Comment by RoseHeavenon Jun 30, 2022 9:18am

155 Views

Post# 34793315

RE:RE:Maintenance Dose

I believe majority of NR cases are coming from 12 underdosed patients which are partially or fully dropped from the maintenance dosage. As per news relkease, total 12 patients out of 38 (32%) in Phase II were disqualified for maintenance dose but counting those 12 patients in calculating response rates. This might be skewing response rates significantly to the downside.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario